首页 > 最新文献

European Journal of Nuclear Medicine and Molecular Imaging最新文献

英文 中文
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia. [18]FDG PET/MR评估原发性纤毛运动障碍儿童和青少年的疾病扩展和炎症。
IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-02-01 Epub Date: 2025-08-30 DOI: 10.1007/s00259-025-07521-7
Silvia Carraro, Valentina A Ferraro, Pietro Zucchetta, Stefania Zanconato, Francesca Serani, Chiara Giraudo, Diego Cecchin

Background: Primary ciliary dyskinesia (PCD) is a rare condition characterized by ciliary dysfunction, impaired mucociliary clearance and mucus accumulation in the airways.

Purpose: Our aim was to evaluate the performance of [18F]FDG PET/MR in assessing structural and inflammatory pulmonary features in patients with PCD, using high-resolution CT (HRCT) as the gold-standard reference.

Materials and methods: We recruited patients with PCD (≥ 7 years) regularly followed at our Regional Center for PCD. They underwent chest HRCT and [18F]FDG PET/MR using sequences optimized for the morpho-functional study of the lung. Parametric PET images were obtained by dividing each voxel by the mean value in a reference area. The volume of interest (VOI in cm3), named Metabolic Inflammatory Volume (MIV), was calculated by thresholding the PET parametric image using a value twice the mean of the reference area. Standardized Uptake Value (SUV) Max, SUV mean, Total Lesion Glycolysis (TLG) and MIV were recorded. HRCT and MR were analyzed using the Eichinger score.

Results: Sixteen patients were enrolled. The Bland-Altman plot showed good agreement between HRCT and MR scores. Cumulative HRCT and MR scores correlated significantly with SUV mean score (HRCT: p = 0.02, rs=0.6; MR: p = 0.006, rs=0.66) and MIV (HRCT: p = 0.003, rs =0.7; MR: p = 0.004, rs =0.69). Total HRCT and MR scores and MIV score inversely correlated with spirometric parameters.

Conclusion: PET/MR proved to be accurate in evaluating disease extent in PCD. It enabled the simultaneous assessment of structural damage and lung inflammation, both of which resulted inversely related to lung function. PET/MR is a promising tool for PCD monitoring.

背景:原发性纤毛运动障碍(PCD)是一种罕见的疾病,其特征是纤毛功能障碍,纤毛粘膜清除受损和气道粘液积聚。目的:我们的目的是评估[18F]FDG PET/MR在评估PCD患者肺部结构和炎症性特征方面的表现,以高分辨率CT (HRCT)作为金标准参考。材料和方法:我们招募了PCD患者(≥7年),在我们的PCD区域中心定期随访。他们接受了胸部HRCT和[18F]FDG PET/MR,使用优化的肺部形态功能研究序列。参数化PET图像由每个体素除以参考区域的平均值得到。感兴趣的体积(VOI,以cm3为单位),称为代谢炎症体积(MIV),通过使用参考区域平均值的两倍的值对PET参数图像进行阈值计算。记录标准化摄取值(SUV) Max、SUV均值、病灶糖酵解总量(TLG)和MIV。采用Eichinger评分对HRCT和MR进行分析。结果:16例患者入组。Bland-Altman图显示HRCT和MR评分吻合良好。累积HRCT和MR评分与SUV平均评分(HRCT: p = 0.02, rs=0.6; MR: p = 0.006, rs=0.66)和MIV (HRCT: p = 0.003, rs= 0.7; MR: p = 0.004, rs= 0.69)显著相关。HRCT和MR总评分及MIV评分与肺量测定参数呈负相关。结论:PET/MR能准确评价PCD病变程度。它可以同时评估结构损伤和肺部炎症,两者的结果与肺功能呈负相关。PET/MR是一种很有前途的PCD监测工具。
{"title":"[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia.","authors":"Silvia Carraro, Valentina A Ferraro, Pietro Zucchetta, Stefania Zanconato, Francesca Serani, Chiara Giraudo, Diego Cecchin","doi":"10.1007/s00259-025-07521-7","DOIUrl":"10.1007/s00259-025-07521-7","url":null,"abstract":"<p><strong>Background: </strong>Primary ciliary dyskinesia (PCD) is a rare condition characterized by ciliary dysfunction, impaired mucociliary clearance and mucus accumulation in the airways.</p><p><strong>Purpose: </strong>Our aim was to evaluate the performance of [18F]FDG PET/MR in assessing structural and inflammatory pulmonary features in patients with PCD, using high-resolution CT (HRCT) as the gold-standard reference.</p><p><strong>Materials and methods: </strong>We recruited patients with PCD (≥ 7 years) regularly followed at our Regional Center for PCD. They underwent chest HRCT and [18F]FDG PET/MR using sequences optimized for the morpho-functional study of the lung. Parametric PET images were obtained by dividing each voxel by the mean value in a reference area. The volume of interest (VOI in cm<sup>3</sup>), named Metabolic Inflammatory Volume (MIV), was calculated by thresholding the PET parametric image using a value twice the mean of the reference area. Standardized Uptake Value (SUV) Max, SUV mean, Total Lesion Glycolysis (TLG) and MIV were recorded. HRCT and MR were analyzed using the Eichinger score.</p><p><strong>Results: </strong>Sixteen patients were enrolled. The Bland-Altman plot showed good agreement between HRCT and MR scores. Cumulative HRCT and MR scores correlated significantly with SUV mean score (HRCT: p = 0.02, r<sub>s</sub>=0.6; MR: p = 0.006, r<sub>s</sub>=0.66) and MIV (HRCT: p = 0.003, r<sub>s</sub> =0.7; MR: p = 0.004, r<sub>s</sub> =0.69). Total HRCT and MR scores and MIV score inversely correlated with spirometric parameters.</p><p><strong>Conclusion: </strong>PET/MR proved to be accurate in evaluating disease extent in PCD. It enabled the simultaneous assessment of structural damage and lung inflammation, both of which resulted inversely related to lung function. PET/MR is a promising tool for PCD monitoring.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2158-2166"},"PeriodicalIF":7.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms. 神经内分泌肿瘤PET显像SSTR2拮抗剂[68Ga]Ga-Asp2-JR11的合成、临床前评价和临床翻译
IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-02-01 Epub Date: 2025-08-30 DOI: 10.1007/s00259-025-07474-x
Zihao Chen, Xingyu Mu, Lei Zhang, Zhisheng Jie, Kadeer Tudi, Haoran Liang, Qingxing Liu, Jingze Li, Weixia Chong, Yufeng Mo, Wei Fu, Ganghua Tang
<p><strong>Purpose: </strong>Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [<sup>68</sup>Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp<sub>2</sub>-PEG<sub>2</sub>- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.</p><p><strong>Methods: </strong>Asp<sub>2</sub>-JR11 was synthesized by modifying the NOTA-JR11 backbone, and its binding properties were evaluated via molecular docking, in vitro assays, and in vivo imaging. Radiolabeling with <sup>68</sup>Ga was performed for Asp<sub>2</sub>-JR11, NOTA-JR11, and DOTA-TATE. We conducted cell uptake, internalization, PET/CT imaging, biodistribution, and blocking studies in AR42J (SSTR2-positive) and HCT116 (SSTR2-negative) tumor models. A first-in-human study included nine patients with NENs who underwent [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 PET/CT and [<sup>18</sup>F]FDG PET/CT imaging, along with dosimetry assessment.</p><p><strong>Results: </strong>Docking analysis showed that Asp<sub>2</sub>-JR11 maintained equivalent binding energy to NOTA-JR11 but formed more hydrogen bonds with SSTR2 (10 vs. 5), suggesting enhanced stability. [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 demonstrated high radiochemical purity (> 95%), higher molar activity (12.9-14.8 GBq/µmol), and greater hydrophilicity (LogD = - 3.18 ± 0.01) than comparators. In AR42J cells, [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 exhibited rapid uptake (9.95 ± 0.10%AD/10⁶ cells at 30 min) and low internalization (17.63 ± 0.91% at 120 min), with significantly higher uptake than [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-NOTA-JR11 in both in vitro and micro PET/CT studies (e.g., 10.67 ± 0.16 vs. 7.79 ± 0.50%ID/g at 30 min, p < 0.05). In vivo imaging and biodistribution confirmed higher tumor-to-background ratios and reduced off-target organ uptake, notably in the kidneys, pancreas, and spleen. Tumor uptake was significantly inhibited by co-injection of SSTR2 ligands, confirming specificity. In human subjects, [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 showed favorable biodistribution and rapid clearance via renal excretion, with the spleen showing the highest transient uptake. Tumors were clearly visualized as early as 12 min post-injection and maintained strong contrast up to 120 min. Dosimetry revealed the highest absorbed dose in the urinary bladder wall (5.78 × 10⁻² mSv/MBq), with an effective whole-body dose of 9.94 × 10⁻³ mSv/MBq. Comparative PET/CT imaging in nine patients (33
目的:生长抑素受体亚型2 (SSTR2)在分化良好的神经内分泌肿瘤(NENs)中过表达,是正电子发射断层扫描(PET)成像的关键靶点。虽然SSTR2激动剂如[68Ga]Ga-DOTA-TATE在临床上被广泛使用,但最近的证据表明,拮抗剂放射配体可以结合更多的受体位点而不诱导内化,可能提供更好的成像性能。在这里,我们报道了[68Ga]Ga-Asp2-JR11的合成、临床前验证和中试临床翻译。[68Ga]Ga-Asp2-JR11是一种新型SSTR2拮抗剂放射配体,具有- asp2 - peg2 -连接体,旨在增强NENs的亲水性和受体接合性,用于PET成像。方法:通过修饰NOTA-JR11骨架合成Asp2-JR11,并通过分子对接、体外实验、体内成像等方法评价其结合性能。用68Ga对Asp2-JR11、NOTA-JR11和DOTA-TATE进行放射性标记。我们在AR42J (sstr2阳性)和HCT116 (sstr2阴性)肿瘤模型中进行了细胞摄取、内化、PET/CT成像、生物分布和阻断研究。一项首次人体研究纳入了9例NENs患者,他们接受了[68Ga]Ga-Asp2-JR11 PET/CT和[18F]FDG PET/CT成像,并进行了剂量学评估。结果:对接分析表明,Asp2-JR11与NOTA-JR11保持了相当的结合能,但与SSTR2形成了更多的氢键(10比5),稳定性增强。[68Ga]Ga-Asp2-JR11具有较高的放射化学纯度(bbb95 %)、较高的摩尔活性(12.9-14.8 GBq/µmol)和亲水性(LogD = - 3.18±0.01)。AR42J细胞,ga [68] Ga-Asp2-JR11表现出快速吸收(9.95±0.10%的广告/ 10⁶细胞在30分钟)和低内化在120分钟(17.63±0.91%),与吸收显著高于ga [68] Ga-DOTA-TATE和ga [68] Ga-NOTA-JR11体外和微型PET / CT的研究(例如,10.67±0.16和7.79±0.50%的id / g(30分钟,68页ga) Ga-Asp2-JR11显示有利biodistribution通过肾脏排泄和快速通关,脾脏显示最高的瞬态吸收。注射后12分钟肿瘤清晰可见,并维持强对比至120分钟。剂量测定显示膀胱壁的最高吸收剂量(5.78 × 10毫西弗/MBq),全身有效剂量为9.94 × 10毫西弗/MBq。9例患者(33个病灶)PET/CT对比成像显示[68Ga]Ga-Asp2-JR11可检出[18F]FDG未检出的21个病灶,尤其是肝脏。对于肝转移,[68Ga]Ga-Asp2-JR11产生更高的SUVmax (8.8 vs. 3.2, p = 0.001)和肿瘤-背景比(6.9 vs. 2.7, p 18F]FDG。结论:[68Ga]Ga-Asp2-JR11是一种新型SSTR2拮抗剂PET探针,与现有药物相比,具有更好的亲水性、受体结合性、肿瘤摄取性和体内稳定性。它的高肿瘤背景对比度和良好的剂量谱强调了它作为临床可翻译的放射配体用于NENs的敏感和特异性PET成像的潜力。
{"title":"Synthesis, preclinical evaluation, and clinical translation of [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.","authors":"Zihao Chen, Xingyu Mu, Lei Zhang, Zhisheng Jie, Kadeer Tudi, Haoran Liang, Qingxing Liu, Jingze Li, Weixia Chong, Yufeng Mo, Wei Fu, Ganghua Tang","doi":"10.1007/s00259-025-07474-x","DOIUrl":"10.1007/s00259-025-07474-x","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp&lt;sub&gt;2&lt;/sub&gt;-PEG&lt;sub&gt;2&lt;/sub&gt;- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 was synthesized by modifying the NOTA-JR11 backbone, and its binding properties were evaluated via molecular docking, in vitro assays, and in vivo imaging. Radiolabeling with &lt;sup&gt;68&lt;/sup&gt;Ga was performed for Asp&lt;sub&gt;2&lt;/sub&gt;-JR11, NOTA-JR11, and DOTA-TATE. We conducted cell uptake, internalization, PET/CT imaging, biodistribution, and blocking studies in AR42J (SSTR2-positive) and HCT116 (SSTR2-negative) tumor models. A first-in-human study included nine patients with NENs who underwent [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 PET/CT and [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT imaging, along with dosimetry assessment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Docking analysis showed that Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 maintained equivalent binding energy to NOTA-JR11 but formed more hydrogen bonds with SSTR2 (10 vs. 5), suggesting enhanced stability. [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 demonstrated high radiochemical purity (&gt; 95%), higher molar activity (12.9-14.8 GBq/µmol), and greater hydrophilicity (LogD = - 3.18 ± 0.01) than comparators. In AR42J cells, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 exhibited rapid uptake (9.95 ± 0.10%AD/10⁶ cells at 30 min) and low internalization (17.63 ± 0.91% at 120 min), with significantly higher uptake than [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TATE and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-NOTA-JR11 in both in vitro and micro PET/CT studies (e.g., 10.67 ± 0.16 vs. 7.79 ± 0.50%ID/g at 30 min, p &lt; 0.05). In vivo imaging and biodistribution confirmed higher tumor-to-background ratios and reduced off-target organ uptake, notably in the kidneys, pancreas, and spleen. Tumor uptake was significantly inhibited by co-injection of SSTR2 ligands, confirming specificity. In human subjects, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 showed favorable biodistribution and rapid clearance via renal excretion, with the spleen showing the highest transient uptake. Tumors were clearly visualized as early as 12 min post-injection and maintained strong contrast up to 120 min. Dosimetry revealed the highest absorbed dose in the urinary bladder wall (5.78 × 10⁻² mSv/MBq), with an effective whole-body dose of 9.94 × 10⁻³ mSv/MBq. Comparative PET/CT imaging in nine patients (33 ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"1532-1548"},"PeriodicalIF":7.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs. 神经胶质瘤pet成像的前沿方法:神经肿瘤学家的当前应用和治疗突破的途径。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-31 DOI: 10.1007/s00259-026-07777-7
Lidia Gatto,Riccardo Mei,Martina Stasolla,Enrico Zuliani,Vincenzo Di Nunno,Alicia Tosoni,Marta Aprile,Stefania Bartolini,Marzia Margotti,Chiara Maria Argento,Stefano Fanti,Enrico Franceschi
PURPOSEPositron emission tomography (PET) has become an increasingly important adjunct to brain MRI in the field of neuro-oncology. PET imaging utilizes radiolabeled tracers, providing in vivo assessment of the metabolic and molecular characteristics of gliomas, thereby providing functional data beyond standard anatomic images. This additional layer of crucial biological insight aids in personalized patient management and treatment decision. In recent years, numerous studies have been carried out for the development and clinical validation of several PET radiotracers in glioma imaging, leading to a substantial improvement in glioma diagnosis, staging, treatment strategy planning as well as in monitoring tumor progression and response to therapy. Ongoing innovations in radiopharmaceutical design have further improved the diagnostic performance of PET by increasing both tracer specificity and tumor detection sensitivity.METHODSIn this review, we summarize recent developments in PET imaging for glioma, with particular emphasis on clinically available amino acid PET tracers. In addition, we provide an overview of emerging theranostic strategies, including peptide receptor radionuclide therapy (PRRT) for meningioma and 177Lu-PSMA-617-based approaches for high-grade glioma.RESULTSThe current guidelines recommend the use of amino acid PET for differentiation of neoplastic from non-neoplastic lesions, for delineation of glioma extent, for non-invasive prediction of molecular information, for grading and prognosis estimation, for differentiation of glioma relapse from treatment-related changes and for the evaluation of treatment response.CONCLUSIONSOverall, this work aims to highlight the role of PET as a complementary imaging modality to MRI and to discuss its potential impact on patient outcomes in neuro-oncological practice.
目的正电子发射断层扫描(PET)在神经肿瘤学领域已成为脑MRI的重要辅助手段。PET成像利用放射性标记示踪剂,提供胶质瘤代谢和分子特征的体内评估,从而提供超出标准解剖图像的功能数据。这额外的一层至关重要的生物学洞察力有助于个性化患者管理和治疗决策。近年来,多种PET示踪剂在胶质瘤成像中的开发和临床验证进行了大量研究,在胶质瘤的诊断、分期、治疗策略规划以及监测肿瘤进展和治疗反应方面取得了实质性进展。放射性药物设计的不断创新进一步提高了PET的诊断性能,增加了示踪剂的特异性和肿瘤检测的敏感性。方法在这篇综述中,我们总结了胶质瘤PET成像的最新进展,特别强调了临床可用的氨基酸PET示踪剂。此外,我们还概述了新兴的治疗策略,包括脑膜瘤的肽受体放射性核素治疗(PRRT)和高级别胶质瘤的基于177lu - psma -617的方法。结果:目前的指南推荐使用氨基酸PET鉴别肿瘤与非肿瘤病变,胶质瘤范围的描绘,分子信息的无创预测,分级和预后评估,胶质瘤复发与治疗相关变化的区分,以及治疗反应的评估。总的来说,这项工作旨在强调PET作为MRI的补充成像方式的作用,并讨论其对神经肿瘤学实践中患者预后的潜在影响。
{"title":"Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.","authors":"Lidia Gatto,Riccardo Mei,Martina Stasolla,Enrico Zuliani,Vincenzo Di Nunno,Alicia Tosoni,Marta Aprile,Stefania Bartolini,Marzia Margotti,Chiara Maria Argento,Stefano Fanti,Enrico Franceschi","doi":"10.1007/s00259-026-07777-7","DOIUrl":"https://doi.org/10.1007/s00259-026-07777-7","url":null,"abstract":"PURPOSEPositron emission tomography (PET) has become an increasingly important adjunct to brain MRI in the field of neuro-oncology. PET imaging utilizes radiolabeled tracers, providing in vivo assessment of the metabolic and molecular characteristics of gliomas, thereby providing functional data beyond standard anatomic images. This additional layer of crucial biological insight aids in personalized patient management and treatment decision. In recent years, numerous studies have been carried out for the development and clinical validation of several PET radiotracers in glioma imaging, leading to a substantial improvement in glioma diagnosis, staging, treatment strategy planning as well as in monitoring tumor progression and response to therapy. Ongoing innovations in radiopharmaceutical design have further improved the diagnostic performance of PET by increasing both tracer specificity and tumor detection sensitivity.METHODSIn this review, we summarize recent developments in PET imaging for glioma, with particular emphasis on clinically available amino acid PET tracers. In addition, we provide an overview of emerging theranostic strategies, including peptide receptor radionuclide therapy (PRRT) for meningioma and 177Lu-PSMA-617-based approaches for high-grade glioma.RESULTSThe current guidelines recommend the use of amino acid PET for differentiation of neoplastic from non-neoplastic lesions, for delineation of glioma extent, for non-invasive prediction of molecular information, for grading and prognosis estimation, for differentiation of glioma relapse from treatment-related changes and for the evaluation of treatment response.CONCLUSIONSOverall, this work aims to highlight the role of PET as a complementary imaging modality to MRI and to discuss its potential impact on patient outcomes in neuro-oncological practice.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"143 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automated long axial field of view PET image processing and kinetic modelling with the TurBO toolbox. 自动长轴视野PET图像处理和动力学建模与TurBO工具箱。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-31 DOI: 10.1007/s00259-026-07769-7
Jouni Tuisku,Santeri Palonen,Henri Kärpijoki,Aino Latva-Rasku,Nelli Tuomola,Harri Harju,Sergey V Nesterov,Vesa Oikonen,Hidehiro Iida,Jarmo Teuho,Chunlei Han,Tomi Karjalainen,Anna K Kirjavainen,Johan Rajader,Riku Klén,Pirjo Nuutila,Juhani Knuuti,Lauri Nummenmaa
PURPOSELong axial field of view (LAFOV) PET imaging requires extensive automation due to the large number of target tissues. Therefore, we introduce an open-source analysis pipeline (TurBO, Turku total-BOdy) for automated preprocessing and kinetic modelling of LAFOV [15O]H2O and [18F]FDG PET data. TurBO enables efficient, reproducible quantification of tissue perfusion and metabolism at regional- and voxel-levels through automated co-registration, motion correction, CT-based region of interest (ROI) segmentation, image-derived input function (IDIF) extraction, and region-specific kinetic modelling.METHODSThe pipeline was validated with Biograph Vision Quadra (Siemens Healthineers) LAFOV PET/CT data from 21 subjects scanned with [15O]H2O and 16 subjects scanned with [18F]FDG. Six CT-segmented ROIs (cortical brain gray matter, left iliopsoas muscle, right kidney cortex and medulla, pancreas, spleen and liver) were used to assess different levels of tissue perfusion and glucose metabolism.RESULTSModel fits showed high quality with consistent estimates at regional and voxel-levels (R2 > 0.83 for [15O]H2O, R2 > 0.99 for [18F]FDG). Manual and automated IDIFs were in concordance (R2 > 0.74 for [15O]H2O, and R2 > 0.78 for [18F]FDG) with minimal bias (< 4% and < 10%, respectively). Manual and CT-segmented ROIs showed strong agreement (R2 > 0.82 for [15O]H2O and R2 > 0.83 for [18F]FDG). Motion correction had little impact on estimates (R2 > 0.71 for [15O]H2O and R2 > 0.78 for [18F]FDG) compared with uncorrected data.CONCLUSIONThe TurBO pipeline provides fully automated and reliable quantification for LAFOV PET data. It substantially reduces manual workload and enables standardized, reproducible assessment of inter-organ perfusion and metabolism.
目的长轴向视场(LAFOV) PET成像需要广泛的自动化,因为大量的目标组织。因此,我们引入了一个开源的分析管道(TurBO, Turku total-BOdy),用于LAFOV [15O]H2O和[18F]FDG PET数据的自动预处理和动力学建模。TurBO通过自动共配准、运动校正、基于ct的感兴趣区域(ROI)分割、图像衍生输入函数(IDIF)提取和区域特定动力学建模,在区域和体素水平上实现高效、可重复的组织灌注和代谢量化。方法使用Biograph Vision Quadra (Siemens Healthineers) LAFOV PET/CT数据对该管道进行验证,这些数据来自21名用[15O]H2O扫描的受试者和16名用[18F]FDG扫描的受试者。采用6个ct分节roi(脑皮质灰质、左髂腰肌、右肾皮质及髓质、胰腺、脾脏和肝脏)评估不同水平的组织灌注和糖代谢。结果模型拟合质量高,在区域和体素水平上的估计一致([15O]H2O的R2 > 0.83, [18F]FDG的R2 > 0.99)。手动和自动idif一致([15O]H2O R2 >.74, [18F]FDG R2 >.78),偏差最小([15O]H2O 0.82, [18F]FDG R2 >.83)。与未校正的数据相比,运动校正对估计的影响很小([15O]H2O R2 > 0.71, [18F]FDG R2 > 0.78)。结论TurBO流水线为LAFOV PET数据的定量分析提供了全自动、可靠的方法。它大大减少了人工工作量,实现了器官间灌注和代谢的标准化、可重复评估。
{"title":"Automated long axial field of view PET image processing and kinetic modelling with the TurBO toolbox.","authors":"Jouni Tuisku,Santeri Palonen,Henri Kärpijoki,Aino Latva-Rasku,Nelli Tuomola,Harri Harju,Sergey V Nesterov,Vesa Oikonen,Hidehiro Iida,Jarmo Teuho,Chunlei Han,Tomi Karjalainen,Anna K Kirjavainen,Johan Rajader,Riku Klén,Pirjo Nuutila,Juhani Knuuti,Lauri Nummenmaa","doi":"10.1007/s00259-026-07769-7","DOIUrl":"https://doi.org/10.1007/s00259-026-07769-7","url":null,"abstract":"PURPOSELong axial field of view (LAFOV) PET imaging requires extensive automation due to the large number of target tissues. Therefore, we introduce an open-source analysis pipeline (TurBO, Turku total-BOdy) for automated preprocessing and kinetic modelling of LAFOV [15O]H2O and [18F]FDG PET data. TurBO enables efficient, reproducible quantification of tissue perfusion and metabolism at regional- and voxel-levels through automated co-registration, motion correction, CT-based region of interest (ROI) segmentation, image-derived input function (IDIF) extraction, and region-specific kinetic modelling.METHODSThe pipeline was validated with Biograph Vision Quadra (Siemens Healthineers) LAFOV PET/CT data from 21 subjects scanned with [15O]H2O and 16 subjects scanned with [18F]FDG. Six CT-segmented ROIs (cortical brain gray matter, left iliopsoas muscle, right kidney cortex and medulla, pancreas, spleen and liver) were used to assess different levels of tissue perfusion and glucose metabolism.RESULTSModel fits showed high quality with consistent estimates at regional and voxel-levels (R2 > 0.83 for [15O]H2O, R2 > 0.99 for [18F]FDG). Manual and automated IDIFs were in concordance (R2 > 0.74 for [15O]H2O, and R2 > 0.78 for [18F]FDG) with minimal bias (< 4% and < 10%, respectively). Manual and CT-segmented ROIs showed strong agreement (R2 > 0.82 for [15O]H2O and R2 > 0.83 for [18F]FDG). Motion correction had little impact on estimates (R2 > 0.71 for [15O]H2O and R2 > 0.78 for [18F]FDG) compared with uncorrected data.CONCLUSIONThe TurBO pipeline provides fully automated and reliable quantification for LAFOV PET data. It substantially reduces manual workload and enables standardized, reproducible assessment of inter-organ perfusion and metabolism.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"103 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid dynamic acquisition of cardiac amyloid radionuclide imaging. 心脏淀粉样蛋白放射性核素成像的快速动态获取。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-30 DOI: 10.1007/s00259-025-07737-7
Brett W Sperry,Eric Burgett,James A Case,Timothy M Bateman
{"title":"Rapid dynamic acquisition of cardiac amyloid radionuclide imaging.","authors":"Brett W Sperry,Eric Burgett,James A Case,Timothy M Bateman","doi":"10.1007/s00259-025-07737-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07737-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"261 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SPECT/CT peak tracer uptake is a strong predictor of aseptic loosening in painful total knee arthroplasty. SPECT/CT峰值示踪剂摄取是疼痛全膝关节置换术中无菌性松动的一个强有力的预测因素。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-30 DOI: 10.1007/s00259-026-07775-9
Helmut Rasch,Randa Elsheikh,George M Avram,Alexandra Leica,Sabrina Chelli,Felix Amsler,Andrej M Nowakowski,Rolf Huegli,Michael T Hirschmann
{"title":"SPECT/CT peak tracer uptake is a strong predictor of aseptic loosening in painful total knee arthroplasty.","authors":"Helmut Rasch,Randa Elsheikh,George M Avram,Alexandra Leica,Sabrina Chelli,Felix Amsler,Andrej M Nowakowski,Rolf Huegli,Michael T Hirschmann","doi":"10.1007/s00259-026-07775-9","DOIUrl":"https://doi.org/10.1007/s00259-026-07775-9","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"42 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model. 心衰死亡和心律失常事件的分层风险:基于1²³-间碘苄基胍的多项logistic模型。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-29 DOI: 10.1007/s00259-026-07776-8
Kenichi Nakajima,Takahiro Doi,Tomoaki Nakata,Takuya Nakahashi,Hayato Tada,Hiroshi Wakabayashi,Hein J Verberne
PURPOSEDifferentiating heart failure-related death (HFD) from arrhythmic events (ArEs) is clinically important for patients with chronic heart failure (CHF), as they have distinct mechanisms and therapeutic strategies. We developed and validated a multivariable model to predict HFD, ArEs, and survival using clinical parameters and cardiac 123I-meta-iodobenzylguanidine (123I-mIBG) images.METHODSWe retrospectively analyzed data derived from 997 patients with CHF (mean age 70 ± 13 years, left ventricular ejection fraction (LVEF) 32% ± 13%) over a mean follow-up of 41 ± 27 months. Outcomes were survival, HFD, or ArEs (including sudden cardiac death). Appropriate implantable cardioverter defibrillator therapy for lethal arrhythmias was included in ArEs. Late heart-to-mediastinum ratios (HMRs) were derived from 123I-mIBG images. A multinomial nested logistic regression model using 2 years of outcomes was constructed (N = 854). Internal validation used a 2:1 development-validation split, repeated 3 times. Model performance was assessed by receiver operating characteristic (ROC) analysis, calibration of predicted vs. actual event rates, survival curves, and sex-specific predictive models.RESULTSSelected variables were age, sex, New York Heart Association (NYHA) functional class, LVEF, hemoglobin, estimated glomerular filtration rate, hypertension, ventricular tachycardia history, and late 123I-mIBG HMR. Areas under ROC curves for survival, HFD, and ArEs in the final 9-variable model were 0.800, 0.717, and 0.838, respectively. The sex-specific 7-variable models showed comparable AUCs of 0.834/0.827 (male/female) for HFD and 0.714/0.826 for ArEs. Risk groups based on median predicted probabilities of HFD and ArEs separated survival curves and corresponded well with actual outcomes.CONCLUSIONSA practical, interpretable model incorporating clinical and 123I-mIBG imaging data enabled reliable and separate prediction of HFD and ArEs, supporting personalized risk stratification in CHF.
目的区分心力衰竭相关死亡(HFD)和心律失常事件(ArEs)对慢性心力衰竭(CHF)患者具有重要的临床意义,因为它们具有不同的机制和治疗策略。我们开发并验证了一个多变量模型,利用临床参数和心脏123i -间碘苄基胍(123I-mIBG)图像来预测HFD、ArEs和生存率。方法回顾性分析997例CHF患者(平均年龄70±13岁,左室射血分数(LVEF) 32%±13%)的资料,平均随访41±27个月。结果为生存、HFD或ArEs(包括心源性猝死)。对致死性心律失常进行适当的植入式心律转复除颤器治疗纳入ArEs。晚期心脏与纵隔比值(HMRs)来源于123I-mIBG图像。使用2年的结果构建多项嵌套逻辑回归模型(N = 854)。内部验证使用2:1的开发验证分割,重复3次。通过受试者工作特征(ROC)分析、预测与实际事件发生率的校准、生存曲线和性别特异性预测模型来评估模型的性能。结果选择的变量包括年龄、性别、纽约心脏协会(NYHA)功能等级、LVEF、血红蛋白、肾小球滤过率、高血压、室性心动过速史和晚期123I-mIBG HMR。在最终的9个变量模型中,生存率、HFD和ArEs的ROC曲线下面积分别为0.800、0.717和0.838。性别特异性的7变量模型显示,HFD的auc为0.834/0.827(男性/女性),ArEs的auc为0.714/0.826。基于HFD和ArEs中位预测概率的风险组分离了生存曲线,与实际结果吻合良好。结论:结合临床和123I-mIBG成像数据的实用、可解释的模型能够可靠、独立地预测HFD和ArEs,支持CHF的个性化风险分层。
{"title":"Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model.","authors":"Kenichi Nakajima,Takahiro Doi,Tomoaki Nakata,Takuya Nakahashi,Hayato Tada,Hiroshi Wakabayashi,Hein J Verberne","doi":"10.1007/s00259-026-07776-8","DOIUrl":"https://doi.org/10.1007/s00259-026-07776-8","url":null,"abstract":"PURPOSEDifferentiating heart failure-related death (HFD) from arrhythmic events (ArEs) is clinically important for patients with chronic heart failure (CHF), as they have distinct mechanisms and therapeutic strategies. We developed and validated a multivariable model to predict HFD, ArEs, and survival using clinical parameters and cardiac 123I-meta-iodobenzylguanidine (123I-mIBG) images.METHODSWe retrospectively analyzed data derived from 997 patients with CHF (mean age 70 ± 13 years, left ventricular ejection fraction (LVEF) 32% ± 13%) over a mean follow-up of 41 ± 27 months. Outcomes were survival, HFD, or ArEs (including sudden cardiac death). Appropriate implantable cardioverter defibrillator therapy for lethal arrhythmias was included in ArEs. Late heart-to-mediastinum ratios (HMRs) were derived from 123I-mIBG images. A multinomial nested logistic regression model using 2 years of outcomes was constructed (N = 854). Internal validation used a 2:1 development-validation split, repeated 3 times. Model performance was assessed by receiver operating characteristic (ROC) analysis, calibration of predicted vs. actual event rates, survival curves, and sex-specific predictive models.RESULTSSelected variables were age, sex, New York Heart Association (NYHA) functional class, LVEF, hemoglobin, estimated glomerular filtration rate, hypertension, ventricular tachycardia history, and late 123I-mIBG HMR. Areas under ROC curves for survival, HFD, and ArEs in the final 9-variable model were 0.800, 0.717, and 0.838, respectively. The sex-specific 7-variable models showed comparable AUCs of 0.834/0.827 (male/female) for HFD and 0.714/0.826 for ArEs. Risk groups based on median predicted probabilities of HFD and ArEs separated survival curves and corresponded well with actual outcomes.CONCLUSIONSA practical, interpretable model incorporating clinical and 123I-mIBG imaging data enabled reliable and separate prediction of HFD and ArEs, supporting personalized risk stratification in CHF.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study. PRKN突变携带者血清素能功能丧失:一项[11C]DASB PET研究。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-29 DOI: 10.1007/s00259-025-07693-2
Edoardo Rosario de Natale,Heather Wilson,Joji P Verghese,Eoin Mulroy,Savvas Antoniadis,Alana Terry,Francesco Cavallieri,Micol Avenali,Pasquale Nigro,Varvara Valotassiou,Eugenii A Rabiner,Stephen Mullin,Nicola Tambasco,Maria Teresa Pellecchia,Georgia Xiromerisiou,Vicky L Marshall,Esther Sammler,Enza Maria Valente,Franco Valzania,Kailash P Bhatia,Marios Politis
{"title":"Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study.","authors":"Edoardo Rosario de Natale,Heather Wilson,Joji P Verghese,Eoin Mulroy,Savvas Antoniadis,Alana Terry,Francesco Cavallieri,Micol Avenali,Pasquale Nigro,Varvara Valotassiou,Eugenii A Rabiner,Stephen Mullin,Nicola Tambasco,Maria Teresa Pellecchia,Georgia Xiromerisiou,Vicky L Marshall,Esther Sammler,Enza Maria Valente,Franco Valzania,Kailash P Bhatia,Marios Politis","doi":"10.1007/s00259-025-07693-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07693-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"44 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic value of [18F]FDG PET/CT for detection of infectious and inflammatory foci in critically ill patients: a systematic review and meta-analysis [18F]FDG PET/CT对危重患者感染和炎症灶的诊断价值:系统综述和荟萃分析
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-28 DOI: 10.1007/s00259-025-07759-1
Giorgio Treglia, Domenico Albano, Xavier Wittebole, Andor W. J. M. Glaudemans, Janesh Pillay, Olivier Gheysens
{"title":"Diagnostic value of [18F]FDG PET/CT for detection of infectious and inflammatory foci in critically ill patients: a systematic review and meta-analysis","authors":"Giorgio Treglia, Domenico Albano, Xavier Wittebole, Andor W. J. M. Glaudemans, Janesh Pillay, Olivier Gheysens","doi":"10.1007/s00259-025-07759-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07759-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria. 多学科团队解释前列腺癌分期期间PSMA PET不确定骨摄取的表现:与PROMISE标准的比较。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-28 DOI: 10.1007/s00259-026-07763-z
Dimitrios Priftakis,Fadilah Aziz,Noora Bin Essa,Reena Davda,Maria Lyasheva,Sudeshna Maitra,Francesco Fraioli,Simon Wan,Jamshed Bomanji,Asim Afaq
PURPOSETo compare the performance of a multidisciplinary team (MDT) with the proposed standardized PROMISE classification system for indeterminate bone uptake on staging PSMA PET.METHODS744 staging PSMA PET/CT scans (140 18F-PSMA-1007 and 604 68Ga-PSMA-11 PET/CT) were retrospectively reviewed for the presence of indeterminate bone metastatic staging. 95 scans which were discussed at an MDT meeting were further analysed for the comparison with the PROMISE classification system. MDT interpretation of the bone staging was recorded as positive or negative, based on risk stratification, imaging review, and clinically suitable management options. Additional resources were occasionally used, such as bone biopsy, musculoskeletal MRI, or re-evaluation after initial androgen deprivation therapy. MDT and PROMISE classification were compared for agreement. Statistical assessment was made on any differences in age, PSA, T-stage, Gleason score, risk, SUVmax and tracer used between negative and positive patients in both methods. Discordant cases were correlated with follow up data.RESULTSThe overall incidence of indeterminate bone uptake in staging PSMA PET scans was 16.9%, reaching 40% for 18F-PSMA-1007. There was substantial agreement between MDT and PROMISE interpretation (87.3%). The MDT was more likely to interpret an indeterminate bone uptake as negative in patients with lower Gleason score and in scans where 18F-PSMA-1007 was used. The data from long-term follow up favoured the MDT interpretation in all the cases of disagreement. Examples of pitfalls in rib or thoracic spine foci of uptake are presented and recommendations for PET reporters and MDTs have been generated based on the results.CONCLUSIONPROMISE may interpret indeterminate bone PSMA uptake with high accuracy. Therefore, PET reporters are recommended to use the PROMISE algorithm, while being mindful of common pitfalls related to the Gleason score, tracer used and anatomical localisation of indeterminate bone findings. Additional discussion in an MDT meeting is recommended with a view to resolve all equivocal findings.
目的比较多学科团队(MDT)与提出的标准化PROMISE分类系统在PSMA PET分期不确定骨摄取方面的表现。方法回顾性分析744例PSMA分期PET/CT扫描(140例18F-PSMA-1007和604例68Ga-PSMA-11 PET/CT)是否存在不确定的骨转移分期。在MDT会议上讨论的95次扫描被进一步分析,以与PROMISE分类系统进行比较。根据风险分层、影像学检查和临床合适的治疗方案,MDT对骨分期的解释被记录为阳性或阴性。偶尔会使用额外的资源,如骨活检、肌肉骨骼MRI或初始雄激素剥夺治疗后的重新评估。比较MDT和PROMISE分类的一致性。对两种方法阴性和阳性患者的年龄、PSA、t分期、Gleason评分、风险、SUVmax和示踪剂的差异进行统计学评价。不一致病例与随访资料相关。结果PSMA分期PET扫描中不确定骨摄取的总发生率为16.9%,18F-PSMA-1007达到40%。MDT和PROMISE解释之间有很大的一致性(87.3%)。在Gleason评分较低的患者和使用18F-PSMA-1007的扫描中,MDT更有可能将不确定的骨摄取解释为阴性。长期随访的数据支持MDT对所有不一致病例的解释。本文介绍了肋骨或胸椎摄取病灶的缺陷,并根据结果对PET报告者和mdt提出了建议。结论promise可以较准确地解释不确定的骨PSMA摄取。因此,建议PET报告者使用PROMISE算法,同时注意与Gleason评分、使用的示踪剂和不确定骨发现的解剖定位相关的常见陷阱。建议在MDT会议上进行进一步讨论,以解决所有模棱两可的发现。
{"title":"Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria.","authors":"Dimitrios Priftakis,Fadilah Aziz,Noora Bin Essa,Reena Davda,Maria Lyasheva,Sudeshna Maitra,Francesco Fraioli,Simon Wan,Jamshed Bomanji,Asim Afaq","doi":"10.1007/s00259-026-07763-z","DOIUrl":"https://doi.org/10.1007/s00259-026-07763-z","url":null,"abstract":"PURPOSETo compare the performance of a multidisciplinary team (MDT) with the proposed standardized PROMISE classification system for indeterminate bone uptake on staging PSMA PET.METHODS744 staging PSMA PET/CT scans (140 18F-PSMA-1007 and 604 68Ga-PSMA-11 PET/CT) were retrospectively reviewed for the presence of indeterminate bone metastatic staging. 95 scans which were discussed at an MDT meeting were further analysed for the comparison with the PROMISE classification system. MDT interpretation of the bone staging was recorded as positive or negative, based on risk stratification, imaging review, and clinically suitable management options. Additional resources were occasionally used, such as bone biopsy, musculoskeletal MRI, or re-evaluation after initial androgen deprivation therapy. MDT and PROMISE classification were compared for agreement. Statistical assessment was made on any differences in age, PSA, T-stage, Gleason score, risk, SUVmax and tracer used between negative and positive patients in both methods. Discordant cases were correlated with follow up data.RESULTSThe overall incidence of indeterminate bone uptake in staging PSMA PET scans was 16.9%, reaching 40% for 18F-PSMA-1007. There was substantial agreement between MDT and PROMISE interpretation (87.3%). The MDT was more likely to interpret an indeterminate bone uptake as negative in patients with lower Gleason score and in scans where 18F-PSMA-1007 was used. The data from long-term follow up favoured the MDT interpretation in all the cases of disagreement. Examples of pitfalls in rib or thoracic spine foci of uptake are presented and recommendations for PET reporters and MDTs have been generated based on the results.CONCLUSIONPROMISE may interpret indeterminate bone PSMA uptake with high accuracy. Therefore, PET reporters are recommended to use the PROMISE algorithm, while being mindful of common pitfalls related to the Gleason score, tracer used and anatomical localisation of indeterminate bone findings. Additional discussion in an MDT meeting is recommended with a view to resolve all equivocal findings.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"2 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Nuclear Medicine and Molecular Imaging
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1